

Effective from Session: 2016-17										
Course Code	MPL101T Title of the Course		Modern Pharmaceutical Analytical Techniques	L	Т	P	с			
Year	I	Semester	I	4	~	~	4			
Pre-Requisite	B.Pharm	Co-requisite - 4 0 0								
Course Objectives 1. Chemicals and Excipients 2. The analysis of various drugs in single and combination dosage forms 3. Theoretical and practical skills of the instruments										

	Course Outcomes
CO1	Investigate the pharmaceutical substance by absorption and emission techniques.
CO2	Appraise the pharmaceutical substance by nuclear magnetic spectroscopy techniques.
CO3	Examine the mass spectroscopy involved for the pharmaceutical substances.
CO4	Recognize the principle, instrumentation and applications of chromatographic techniques.
CO5	Sketch the principle, instrumentation and applications of electrophoresis and x-ray crystallography.
CO6	Apprehend the fundamentals of immunological assays.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	UV-Visible spectroscopy, IR spectroscopy, Spectroflourimetry , Flame emission spectroscopy and Atomic absorption spectroscopy	UV-Visible spectroscopy: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy, Difference/Derivative spectroscopy. IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier -Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy, Data Interpretation. Spectroflourimetry: Theory of Fluorescence, Factors affecting fluorescence (Characteristics of drugs that can be analysed by flourimetry), Quenchers, Instrumentation and Applications of fluorescence spectrophotometer. Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation, Interferences and Applications.	10	1
2	NMR spectroscopy	NMR spectroscopy: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT-NMR and 13C NMR. Applications of NMR spectroscopy.	10	2
3	Mass Spectroscopy	Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy.	10	3
4	Chromatography	Chromatography: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution, isolation of drug from excipients, data interpretation and applications of the following: a) Thin Layer chromatography b) High Performance Thin Layer Chromatography c) Ion exchange chromatography d) Column chromatography e) Gas chromatography f) High Performance Liquid chromatography g) Ultra High Performance Liquid chromatography h) Affinity chromatography i) Gel Chromatography	10	4
5	Electrophoresis and X-ray Crystallography	Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following: Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing X ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.	10	5
6	Potentiometry and Thermal Techniques	Potentiometry: Principle, working, Ion selective Electrodes and Application of potentiometry. Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications.	10	6

Reference Books:

Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004. Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998. Instrumental methods of analysis - Willards, 7th ett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991. Quantitative of Drugs in Pharmacedition, CBS publishers. Pharmaceutical Analysis - Modern Methods - Part B - J W Munson, Vol 11, Marcel. Dekker Series Analysis Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi. Textbook of Pharmaceutical Analysis, KA.Connors, 3rd Edition, John Wiley & Sons, 1982.

e-Learning Source:

https://www.classcentral.com/course/swayam-spectroscopic-techniques-for-pharmaceutical-and-biopharmaceutical-industries-14301

https://www.sciencedirect.com/science/article/pii/S1878535213001056

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258797/

https://www.google.co.in/books/edition/Pharmaceutical_Analysis/Ub8wod1CJ50C?hl=en&gbpv=1&dq=pharmaceutical+analysis+spectral+chromatog raphv&printsec=frontcover

https://www.google.co.in/books/edition/Pharmaceutical_Analysis_E_Book/YExgDAAAQBAJ?hl=en&gbpv=1&dq=pharmaceutical+analysis+spectral +chromatographv&printsec=frontcover

	Course Articulation Matrix: (Mapping of COs with POs and PSOs)																	
PO- PSO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO																		
C01	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-
CO2	3	3	3	2	3	3	2	3	3	3	3	-	3	3	3	-	-	-
CO3	3	3	3	2	3	3	2	2	3	2	3	-	3	3	3	-	-	-
CO4	3	3	3	3	3	2	2	2	3	3	3	-	3	3	3	-	-	-
CO5	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-
CO6	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2016-2017									
Course Code	MPL 102 T	Title of the Course	itle of the Course Advance Pharmacology - I L		Т	Р	С		
Year	Ι	Semester	Ι	4	0		4		
Pre-Requisite	B.Pharm Co-requisite –			4	0	0	4		
Course Objectives	2.Explain the	mechanism of drug acti	narmacotherapy of certain diseases ons at cellular and molecular level traindications and clinical uses of drugs used in treatment of	f disea	ses				

	Course Outcomes
CO1	After studying this subject students will learn regarding the pharmacokinetics and pharmacodynamics of drugs. Students will have the
	knowledge about the receptor and types of receptors and their examples. Can explain about the effect on efficacy of drugs on changes of
	absorption, distribution, metabolism and excretion.
CO2	Upon successful completion of this unit the students will have a deep understanding of neurotransmission. Neurohumoral transmission in
	ANS and CNS and NANC transmission. Apart from this the course provides the detail of various
	sympathomimetic,sympatholytic,parasympathomimetic and parasympatholytic.
CO3	This unit provide the knowledge about the drugs which act on CNS. Also provide the detail knowledge of pharmacology of CNS acting drugs
CO4	This unit provide the detail knowledge of drugs acting on cardiovascular system particularly antihypertensive, antianginal, antiarrythmic and
	drugs used in congestive heart failure
CO5	provide detailed knowledge about the different autacoids and their receptors, physiological and pathological role of
	prostaglandin, histamines, serotonin and dopamine, their agonist and antagonist.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	General Pharmacology	Pharmacokinetics: The dynamics of drug absorption, distribution, biotransformation and elimination. Concepts of linear and non-linear compartment models. Significance of Protein binding. Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. Receptors, structural and functional families of receptors, quantitation of drug receptors interaction and elicited effects.	12	3
2	Neurotransmission	General aspects and steps involved in neurotransmission. Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters– Adrenaline and Acetyl choline). Neurohumoral transmission in the central nervous system (Detailed study about neurotransmitters– histamine, serotonin, dopamine, GABA, glutamate and glycine]. Non adrenergic non cholinergic transmission (NANC). Co– transmission Systemic Pharmacology A detailed study on pathophysiology of diseases, mechanism of action, pharmacology and toxicology of existing as well as novel drugs used in the following systems Autonomic Pharmacology Parasympathomimetics and lytics, sympathomimetics and lytics, agents affecting neuromuscular junction	12	2
3	Central Nervous System Pharmacology	General and local anesthetics Sedatives and hypnotics, drugs used to treat anxiety. Depression, psychosis, mania, epilepsy, neurodegenerative diseases. Narcotic and non-narcotic analgesics.	12	3
4	Cardivascular Pharmacology	Diuretics, antihypertensives, antiischemics, anti-arrhythmics, drugs for heart failure and hyperlipidemia. Hematinics, coagulants, anticoagulants, fibrinolytics and anti- platelet drugs	12	3
5	Autocoid Pharamcology	The physiological and pathological role of Histamine, Serotonin, Kinins Prostaglandins Opioid autocoids. Pharmacology of antihistamines, 5HT antagonists.	12	2

Reference Books:

The Pharmacological Basis of Therapeutics, Goodman and Gillman's

Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.

Basic and Clinical Pharmacology by B.G Katzung

Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.

Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.

Graham Smith. Oxford textbook of Clinical Pharmacology.

Avery Drug Treatment

Dipiro Pharmacology, Pathophysiological approach.

Green Pathophysiology for Pharmacists.

Robbins & Cortan Pathologic Basis of Disease, 9th Ed. (Robbins Pathology)

A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company

KD. Tripathi. Essentials of Medical Pharmacology.

Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers. Clinical Pharmacokinetics & Pharmacodynamics : Concepts and Applications - Malcolm Rowland and Thomas N.Tozer, Wolters Kluwer, Lippincott

Williams & Wilkins Publishers. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists. Modern Pharmacology, Craig CR. & Stitzel RE, Little Brown & Company.

e-Learning Source:

https://education.baystatehealth.org/sites/default/files/St.%20Jean%20-%20Advanced%20Pharmacology%20for%20nursing.pdf

						C	ourse /	Articul	ation I	Matrix.	(Manni	ng of CO	s with PO	s and PS	() (s)			
PO-							ourse 1	<u>si ticu</u>			լուզիրը			s and 1 S	03)			
PS	PO	PO	PO	PO	PO	PO	PO 7	PO	PO	PO1	PO1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
0 C0	1	2	3	4	5	6	./	8	9	0	1							
CO 1	3	3	3	2	3	2	2	2	3	2	3	-	3	3	3	-	-	-
CO 2	3	3	3	2	3	3	2	3	3	3	3	_	3	3	3	-	_	-
CO 3	3	3	3	2	3	3	2	2	3	2	3	_	3	3	3	-	-	_
CO 4	3	3	3	3	3	2	2	2	3	3	3	_	3	3	3	-	_	-
CO 5	3	3	3	2	3	2	2	2	3	2	3	—	3	3	3	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD	



Effective from Session: 2016-2017									
Course Code	MPL103T	Title of the Course	Pharmacological and Toxicological Screening MethodsS - I	L	Т	Р	C		
Year	Ι	Semester	Ι	4	0	•	4		
Pre-Requisite	B.Pharm	Co-requisite	-	4	0	U	4		
Course Objectives	 2. Appraise th 3. describe th animals. 4. Describe th development. 	ne various animals usec e various preclinical e	requirement for the usage of experimental animals I in the drug discovery process and good laboratory practic valuations of drugs and recent experimental techniques in						

	Course Outcomes
CO1	Appreciate the knowledge gained on preclinical evaluation of drugs and recent experimental techniques in the drug discovery and
	development.
CO2	Understood the various of laboratory animals and their maintenance as per the guidelines and also describe good laboratory practices in
	maintenance and handling of experimental animals
CO3	Appraised the regulations and ethical requirements for the usage of experimental animals.
CO4	Learn and describe the various preclinical screening methods (in-vitro and in-vivo) involved in the drug discovery process.
CO5	Learn and describe the various preclinical screening methods (in-vitro and in-vivo) involved in the drug discovery process.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Laboratory animals	Common lab animals: Description, handling, Applications of different species and strains of animals. Transgenic animals: Production, maintenance and applications Anaesthesia & euthanasia of experimental animals Maintenance and breeding of laboratory animals CPCSEA guidelines to conduct experiments on animals, GLP, Bioassay-Principle, scope and limitations, Bioassay methods.	12	1, 2, 3
2	Preclinical screening of new substances	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. CNS Pharmacology: Behavioural and muscular coordination, CNS stimulants, Anxiolytics, antidepressants, antipsychotics, Antiparkonson's drug, Antialzheimer's drug, antiepileptics etc.) Preclinical screening methods of drug acting on ANS.	12	1,4
3	Preclinical screening of new substances	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Respiratory Pharmacology: Anti-asthmatics, Drugs for COPD, Anti-allergics, Aphrodisiacs agents, Antifertility agents, Antiinflammatory agents, Analgesics agents & Antipyretic agents, Gastrointestinal drugs: Anti ulcer, Anti-emetic & Anti-diarrhea, Laxatives.	12	1,4
4	Preclinical screening of new substances	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Drug acting on CVS. Antihypertensive, antiarrythemics, antianginal, antiatherosclerotic, diuretics, antidiabetics, anticancer, hepatoprotectives.	12	1,4
5	Preclinical screening of new substances	Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models. Immunosuppressants, Immunomodulators, General principles of immunoassay: theoretical basis and optimization of immunoassay, Heterogeneous and homogenous immunoassay systems, Immunoassay methods evaluation, Protocol outline, Objectives and preparation, Immunoassay for digoxin and insulin, Limitations of animal experimentation and alternate animal experiments, Extrapolation of in vitro data to preclinical and preclinical to humans.	12	4, 5

Reference Books:

Biological standardization by J.H. Burn D.J. Finney and I.G. Goodwin

Screening methods in Pharmacology by Robert Turner. A

Evaluation of drugs activities by Laurence and Bachrach

Methods in Pharmacology by Arnold Schwartz.

Fundamentals of experimental Pharmacology by M.N.Ghosh

Pharmacological experiment on intact preparations by Churchill Livingstone

Drug discovery and Evaluation by Vogel H.G.

Experimental Pharmacology by R.K.Goyal.

Preclinical evaluation of new drugs by S.K. Guta

Handbook of Experimental Pharmacology, SK.Kulkarni

Practical Pharmacology and Clinical Pharmacy, SK.Kulkarni, 3rd Edition.

David R.Gross. Animal Models in Cardiovascular Research, 2nd Edition, Kluwer Academic Publishers, London, UK.

Screening Methods in Pharmacology, Robert A.Turner.

Rodents for Pharmacological Experiments, Dr. Tapan Kumar chatterjee.

Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi (Author), Ajay Prakash (Author)

e-Learning Source:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127354/

			-			Cour	se Arti	culatio	n Matri	ix: (Map	ping of (COs with	POs and	d PSOs)	_			
PO- PSO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO																		
CO1	3	3	1	2	0	1	3	1	0	0	2	-	3	2	1	-	-	-
CO2	3	3	2	3	0	2	1	1	0	0	3	-	1	1	1	-	-	-
CO3	3	3	2	1	1	0	1	2	0	1	3	-	1	1	1	-	-	-
CO4	3	3	2	1	1	1	2	1	1	0	2	-	3	2	1	-	-	-
CO5	3	3	3	1	1	1	2	1	0	0	3	-	3	2	1	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2016	5-2017											
Course Code MPL104T Title of the Course Cellular and Molecular Pharmacology L T P												
Year I Semester I 4												
Pre-Requisite	-Requisite B Pharm Co-requisite – 4 0											
Course Objectives	2 Explain the 3. Appreciate			proce	ss.							

	Course Outcomes
CO1	Explain the receptor signal transduction process. Can able to answer the difference between necrosis and autophagy and understand the pathways of Apoptosis.
CO2	Describe about the receptor classification and their molecular structure. Able to correlate the drug action with the receptor stimulation.
CO3	Analyze the applicability of molecular pharmacology and biomarkers in drug discovery process.
CO4	Describe about immunomodulators. explain the Applications of gene therapy & Proteomics in management of specific disorders.
CO5	Demonstrate molecular biology techniques as applicable for pharmacology.

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO				
1	Cell biology	Structure and functions of cell and its organelles Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene Sequencing Cell cycles and its regulation. Cell death– events, regulators, intrinsic and extrinsic pathways of apoptosis. Necrosis and autophagy.	12	1				
2	Cell signaling	Intercellular and intracellular signaling pathways. Classification of receptor family and molecular structure ligand gated ion channels; G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors. Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5-trisphosphate, (IP3), NO, and diacylglycerol. Detailed study of following intracellular signaling pathways: cyclic AMP signaling pathway, mitogen-activated protein kinase (MAPK) signaling, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway.	12	2				
3	Principles and applications of genomic and proteomic tools DNA electrophoresis, PCR (reverse transcription and real time), Gene sequencing, micro array technique, SDS page, ELISA and western blotting. Recombinant DNA technology and gene therapy							
4	Pharmacogenomics	Gene mapping and cloning of disease gene. Genetic variation and its role in health/ pharmacology Polymorphisms affecting drug metabolism Genetic variation in drug transporters Genetic variation in G protein coupled receptors Applications of proteomics science: Genomics, proteomics, metabolomics, functionomics, nutrigenomics Immunotherapeutics Types of immunotherapeutics, humanisation antibody therapy, Immunotherapeutics in clinical practice	12	4				
5	Cell culture techniques & Biosimilars	 a. Cell culture techniques Basic equipments used in cell culture lab. Cell culture media, various types of cell culture, general procedure for cell cultures; isolation of cells, subculture, cryopreservation, characterization of cells and their application. Principles and applications of cell viability assays, glucose uptake assay, Calcium influx assays Principles and applications of flow cytometry b. Biosimilars 	12	5				
Referen	ce Books:							
1. The C	ell, A Molecular Approa	ich. Geoffrey M Cooper.						
2. Pharm	acogenomics: The Searc	ch for Individualized Therapies. Edited by J. Licinio and M -L. Wong						
3. Handb	oook of Cell Signaling (S	Second Edition) Edited by Ralph A. et.al						
4. Molec	ular Pharmacology: From	m DNA to Drug Discovery. John Dickenson et.al						
5. Basic	Cell Culture protocols b	y Cheril D.Helgason and Cindy L.Miller						
6. Basic	Cell Culture (Practical A	Approach) by J. M. Davis (Editor)						

7. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)

8. Current porotocols in molecular biology vol I to VI edited by Frederick M.Ausuvel et la.

e-Learning Source:

https://pubmed.ncbi.nlm.nih.gov/9176893/

					_	Cour	se Arti	culatio	n Matr	ix: (Map	ping of (COs with	POs and	l PSOs)				
PO- PSO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
СО																		
CO1	2	3	1	3	2	3	1	1	1	1	1	-	2	3	3	-	-	-
CO2	2	2	1	3	2	3	1	1	1	1	1	-	2	3	3	-	-	-
CO3	2	3	0	3	2	1	0	0	1	1	1	-	3	2	3	-	-	-
CO4	2	3	0	3	2	0	0	1	1	1	1	-	2	2	3	-	-	-
CO5	2	3	0	3	2	0	0	0	1	1	1	-	2	2	3	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 201	6 - 2017											
Course Code	MPL105P	Title of the Course	Pharmacology Practical I	L	Т	Р	C					
Year	I Semester I											
Pre-Requisite	B.Pharm	Co-requisite	_	0	U	12	0					
	1. Discuss th	e pathophysiology phar	macotherapy of certain diseases.									
Course Objectives	2. Explain th	e mechanism of drug ac	ctions at cellular molecular level.									
	3. Understan	d the adverse effects, co	ontraindications and clinical uses of drugs used in treatment	of dise	ease.							

		Course Outcomes		
CO1		poeil compounds and their formulatios.		
CO2		ve and qualitative analysis. Interpret the result of spectral and chromatographical techniques		
CO3	knowledge about the r absorption, distributio of neurotransmission.	oject students will learn regarding the pharmacokinetics and pharmacodynamics of drugs. S receptor and types of receptors and their examples. Can explain about the effect on efficacy n, metabolism and excretion. Upon successful completion of this unit the students will have Neurohumoral transmission in ANS and CNS and NANC transmission. Apart from this the athomimete,sympatholytic,parasympathomimete and parasympatholytic	of drugs on the deep un	changes of derstanding
CO4	This unit provides kn drugs. This unit provid	owledge about the drugs which act on CNS. Also provide the details knowledge of pharmac des the detail knowledge of drugs acting on cardiovascular system particularly antihyperten gs used in congestive heart failure.		
CO5	Provide detail knowle	dge about the different autocoids and their receptors, physiological and pathological role of ne, serotonin and dopamine, their agonist and antagonist.		
Experiment No.	Title of the Experiment	Contact Hrs.	Mapped CO	
1	Compounds analysis	Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer	4	1
2	Component estimation	Simultaneous estimation of multi component containing formulations by UV spectrophotometry.	4	1
3	HPLC	Experiments based on HPLC	4	1
4	Gas chromatography	Experiments based on Gas Chromatography.	4	2
5	Riboflavin estimation	Estimation of riboflavin/quinine sulphate by fluorimetry.	4	2
6	Sodium estimation	4	2	
7	Dtrug administration	4	3	
8	Anaesthesia ,Euthanesia	Techniques of blood sampling, anesthesia and euthanasia of experimental animals	4	3
9	Battery test	Functional observation battery tests (modified Irwin test)	4	3
10	Evaluation CNS stimulant	Evaluation of CNS stimulant, depressant, anxiogenics and anxiolytic, anticonvulsant activity	4	3
11	Drug evaluation	Evaluation of analgesic, anti-inflammatory, local anesthetic, mydriatic and miotic activity.	4	3
12	Diuretic evaluation	Evaluation of diuretic activity	4	3
13	Drug evaluation	Evaluation of antiulcer activity by pylorus ligation method.	4	3
14	Glucose tolerance test	Oral glucose tolerance test	4	4
15	DNA isolation	Isolation and identification of DNA from various sources (Bacteria, Cauliflower, onion, Goat liver).	4	4
16.	RNA isolation	Isolation of RNA from yeast	4	4
17.	Protein estimation	Estimation of proteins by Braford/Lowry's in biological samples	4	4
18	RNAestimation	Estimation of RNA/DNA by UV Spectroscopy	4	4
19.	Gene amplification	Gene amplification by PCR	4	4
20.	Protein quantoification	Protein quantoification western blotting.	4	4
21.	Assays	Enzyme based in-vitro assays (MPO,AChEs, α amylase, α glucosidase).	4	4
22	Assays	Cell viability assays (MTT/Trypan blue/SRB).	4	4
23	DNA fragmentation	DNA fragmentation assay by agarose gel electrophoresis	4	4



24	.DNA damage	DNA damage study by Comet assay	4	5
25	Apoptosis determination	Apoptosis determination by fluorescent imaging studies	4	5
26.	Drug data analysis	Pharmacokinetic studies and data analysis of drugs given by different routes of administration using softwares	4	5
27	Enzyme inhibition	Enzyme inhibition and induction activity	4	5
28	Drug extraction	Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (UV)	4	5
29	Drug extraction	Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (HPLC)	4	5

Reference Books:

CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines,

Fundamentals of experimental Pharmacology by M.N.Ghosh

Handbook of Experimental Pharmacology by S.K. Kulkarni.

Drug discovery and Evaluation by Vogel H.G.

Spectrometric Identification of Organic compounds - Robert M Silverstein,

Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman,

Vogel's Text book of quantitative chemical analysis - Jeffery, Basset, Mendham, Denney,

Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille

Basic Cell Culture (Practical Approach) by J. M. Davis (Editor)

Animal Cell Culture: A Practical Approach by John R. Masters (Editor)

Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi(Author), Ajay Prakash (Author) Jaypee brothers' medical publishers Pvt. Ltd

e-Learning Source:

Animal simulation Ex- Pharm

https://www.pdfdrive.com/drug-discovery-and-evaluation-e33529234.html

				Course	e Articu	lation M	latrix:	(Mapp	ing of (COs wit	h POs a	and PSC	Ds)					
PO- PSO	PO1	PO2	PO3	PO4	PO5	Р Об	PO 7	PO8	PO9	PO1 0	PO1 1	PO1 2	PSO 1	PSO 2	PSO 3	PSO 4	PSO 5	PSO 6
CO											-	_	_	_	-	-	-	
CO1	3	3	3	2	2	3	2	1	1	1	1	-	3	3	3	-	-	-
CO2	3	3	3	3	2	2	2	2	1	1	1	-	3	3	3	-	-	-
CO3	3	3	3	3	3	2	2	3	1	1	1	-	3	3	3	-	-	-
CO4	3	3	3	3	2	2	2	2	1	1	1	-	3	3	3	-	-	-
CO5	3	3	3	3	3	3	2	2	2	1	1	-	3	3	3	-	-	-



Effective from Session: 2016	-2017						
Course Code	MPL201T	Title of the Course	Advanced Pharmacology-II	L	Т	Р	С
Year	Ι	Semester	II				10
Pre-Requisite		Co-requisite		4	0	0	10
Course Objectives	applications of 2. The course 3. To provide several regula 4. The course bioactive mol 5. To provide which would 6. This course	of drugs. provide basic knowledge skills for selection of atory ethical guidelines of e will emphasize on m ecules, and their pharma a strong foundation re be a framework for futu- se is designed to provide	of Pharmacology and toxicology, Advanced pharmacol ge of toxicity and its management and principles of bioassay experimental models in order to screen different pharmacol concerned with it. tolecular signalling concepts of drugs with special attention acokinetic and pharmacodynamic profile. garding chronopharmacology, immunopharmacology and ge re pharmacological approach to a specific problem in the field be basic understanding in the principles of clinical Pharm ness concerned with clinical Pharmacological experiments.	of dif logical on giv ene-ba	ferent of agents ren to e used Pha drug de	lrugs along endoge armaco velopm	with nous ology nent.

	Course Outcomes
CO1	Analyze the different types of endocrine hormones and their role, Molecular & Cellular MOA. Further can understand the deficiency and excess release related endocrine disorders and their therapy.
CO2	Able to explain the MOA and the resistance of antimicrobial agents including antivirals and Anti TB in cellular and molecular level
CO3	Demonstrate the safe applications of Antiprotozoal & Anticancer drugs in clinical and it also explain about the role of inflammatory mediators role in Asthma, Hypersensitivity reaction.
CO4	They can co-relate the pathophysiology behind Gastric ulcer and their therapy with conventional drugs along with new therapeutic approaches.
CO5	Correlate about free radical generation with diseased conditions and their therapy with antioxidants, they can also explain about chronotherapy and Recent Advances in treatment of neurodegenerative disease, Cancer, Diabetes Mellitus

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO							
1	contraceptives, Corticosteroids. Drugs affecting calcium regulation.										
2	2 Chemotherapy Cellular and molecular mechanism of actions and resistance of antimicrobial agents such as β-lactams, aminoglycosides, quinolones, Macrolide antibiotics. Antifungal, antiviral, and anti-TB drugs.										
3	Chamatherapy of cancer Immunopharmecology Callular and hischemical mediators of										
4	GIT Pharmacology	Antiulcer drugs, Prokinetics, antiemetics, anti-diarrheals and drugs for constipation and irritable bowel syndrome. Chronopharmacology Biological and circadian rhythms, applications of chronotherapy in various diseases like cardiovascular disease, diabetes, asthma and peptic ulcer.	12	4							
5	Free radicals Pharmacology	Generation of free radicals, role of free radicals in etiopathology of various diseases such as diabetes, neurodegenerative diseases and cancer. Protective activity of certain important antioxidant Recent Advances in Treatment: Alzheimer's disease, Parkinson's disease, Cancer, Diabetes mellitus	12	5							
Referen	ce Books:										
The Pha	rmacological basis of th	erapeutics- Goodman and Gill man's									
Principle	es of Pharmacology. The	Pathophysiologic basis of drug therapy by David E Golan et al.									
Basic an	d Clinical Pharmacolog	y by B.G -Katzung									
Pharmac	cology by H.P. Rang and	M.M. Dale.									
Hand bo	ok of Clinical Pharmaco	okinetics by Gibaldi and Prescott.									
Text boo	ok of Therapeutics, drug	and disease management by E T. Herfindal and Gourley.									
Applied	biopharmaceutics and P	harmacokinetics by Leon Shargel and Andrew B.C.Yu.									
Handboo	ok of Essential Pharmac	okinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists									
Robbins	& Cortan Pathologic Ba	asis of Disease, 9th Ed. (Robbins Pathology)									
A Comp	lete Textbook of Medica	al Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.									
	athi. Essentials of Medi										
		e Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J,Arm ppincott Williams & Wilkins Publishers	strong, Apri	l W,							
e-Lear	ning Source:										

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888811/
https://drive.google.com/file/d/1xZUXCeoMIvKUDLgplZPnPl8NplnaIVvK/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1AsToYm8V_eJs-QhFyORilu4x9snQwYmU/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1GV4XAflBasfUgO68tBL1EM5CofZvKEs0/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1xhWz7Biu5F0Pl4DlwfMRnTKxvsTicJ0c/view?usp=drive_web&authuser=0
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278270/
https://drive.google.com/file/d/1GV4XAflBasfUgO68tBLIEM5CofZvKEs0/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1VSvRcGydpXgW0unslqxoUpoig9O-VdsP/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1bmNQZkN38cHHXqNjBnyCGDImTUs81stp/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1VSvRcGydpXgW0unslqxoUpoig9O-VdsP/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1kKeE_ycwo0jrkL2xHOMuDdh5Y9lf87cK/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1yowFP4zAxUe6jJiSMl01C6DYa5zhMvYY/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1HMhLQL18qsZQZhUB2WsdGU8_zjTSA9Yr/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1kKeE_ycwo0jrkL2xHOMuDdh5Y9lf87cK/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1SVYepkRVdIi8AzXlquQW_A5O04YGq2fM/view?usp=drive_web&authuser=0
https://drive.google.com/file/d/1yowFP4zAxUe6jJiSMl01C6DYa5zhMvYY/view?usp=drive_web&authuser=0

		_	_			Cour	se Arti	culatio	n Matri	ix: (Map	ping of (COs with	POs and	l PSOs)				
PO- PSO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO																		
CO1	2	3	1	3	2	3	1	1	1	1	1	-	2	3	2	-	-	-
CO2	2	2	1	3	2	3	1	1	1	1	1	-	2	3	2	-	-	-
CO3	2	3	0	3	2	1	0	0	1	1	1	-	3	2	3	-	-	-
CO4	2	3	0	3	2	0	0	1	1	1	1	-	2	2	2	-	-	-
CO5	2	3	0	3	2	0	0	0	1	1	1	-	2	2	2	-	-	-

Name & Sign of Program Coordinator	
	Sign & Seal of HoD



Effective from Session: 2016	Effective from Session: 2016-2017								
Course Code	MPL 202 T	Title of the Course	Pharmacological and Toxicological Screening Methods - II	L	Т	Р	С		
Year	Ι	Semester	Semester II 4 0 0						
Pre-Requisite	B.Pharm	Co-requisite	_	4	U	U	4		
	1. Explain the	e various types of toxicit	ty studies.						
Course Objectives	2. Appreciate	2. Appreciate the importance of ethical and regulatory requirement for toxicity studies.							
	3. Demonstra	te the practical skills rec	quire to conduct toxicity studies.						

	Course Outcomes									
CO1	Explore various types of toxicological studies and its regulatory guidelines including OECD principle of good laboratory practice.									
CO2	Explicate OECD principle of good laboratory practice.									
CO3	Design, conduct and analyze various screening methods employed for conducting toxicological studies in drug discovery and development.									
CO4										
CO5	Utilized various Alternative methods for animal toxicity testing employed in drug discovery and development.									

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO				
1	Toxicology	Toxicology Basic definition and types of toxicology (general, mechanistic, regulatory and descriptive), OECD,ICH & EPA guidelines for conducting toxicity studies, GLP						
2	Toxicity studies	12	3					
3	Reproductive toxicity studies	Male Reproductive toxicology studies, Female reproductive studies (segment I and segment III), Teratogenecity studies (segment II), Genotoxicity studies (Ames Test), In vitro and in vivo Micronucleus and Chromosomal aberrations studies), In vivo carcinogenicity studies.	12	3				
4	IND	12	4					
5	Toxicokinetics	Toxicokinetics In Preclinical studies, saturation kinetics, Importance, Applications, Alternative methods to animal toxicity study.	12	5				

Reference Books:

Principles of Toxicology by Karen E. Stine, Thomas M. brown.

OECD guidelines

Animal models in Toxicology by Lower and Bariyan.

Drug from discovery to approval by Rick NG.

e-Learning Source:

https://education.baystatehealth.org/sites/default/files/St.%20Jean%20-%20Advanced%20Pharmacology%20for %20nursing.pdf

		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO- PSO CO	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO1	2	3	1	3	2	3	1	1	1	1	1	-	2	3	2	-	-	-
CO2	2	2	1	3	2	3	1	1	1	1	1	-	2	3	2	-	-	-
CO3	2	3	0	3	2	1	0	0	1	1	1	-	3	2	2	-	-	-
CO4	2	3	0	3	2	0	0	1	1	1	1	-	2	2	2	-	-	-
CO5	2	3	0	3	2	0	0	0	1	1	1	-	2	2	2	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2016	-2017					-		
Course Code	MPL203T	Title of the Course	Principles of Drug Discovery	L	Т	Р	С	
Year	Ι	Semester II						
Pre-Requisite	B.Pharm.	Co-requisite	-	3	1	0	4	
Course Objectives	 Appreciate Explain var Explain var 	rious targets for drug dis rious lead seeking metho	ole of genomics, proteomics and bioinformatics in drug disc	overy.				

	Course Outcomes
CO1	Explain the various stages of drug discovery
CO2	Appreciate the importance of the role of genomics, proteomics and bioinformatics in drug discovery
CO3	Explain various targets for drug discovery
CO4	Explain various lead seeking method and lead optimization
CO5	Appreciate the importance of the role of computer aided drug design in drug discovery

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Drug Discovery Process	An Overview of Modern Drug Discovery Process: Target identification, target validation, lead identification and lead optimization. Economics of drug discovery. Target discovery and validation-Role of genomics, proteomics and bioinformatics. Role of nucleic acid microarrays, protein microarrays, antisense technologies, siRNAs, antisense oligonucleotides, zinc finger proteins. Role of transgenic animals in target validation	12	1, 2, 3, 4, 5
2	Lead identification and in silico techniques	Lead Identification: combinatorial chemistry & high throughput screening, in silico lead discovery techniques. Assay development for hit identification. Protein structure: Levels of protein structure, domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modeling methods. Application of NMR and X-ray crystallography in protein structure prediction.	12	1, 2, 3, 4, 5
3	Rational drug design	Rational Drug Design: Traditional vs rational drug design, methods followed in traditional drug design, high throughput screening. Concepts of rational drug design. Rational drug design methods: Structure and pharmacophore based approaches. Virtual Screening techniques: Drug likeness screening, concept of pharmacophore mapping and pharmacophore based screening.	12	1, 2, 3, 4, 5
4	Docking	Molecular Docking: Rigid docking, flexible docking, manual docking: Docking based screening. De novo drug design. Quantitative analysis of structure activity relationship: History and development of QSAR, SAR versus QSAR, physicochemical parameters, Hansch analysis, Fee-Wilson analysis and relationship between them.	12	1, 2, 3, 4, 5
5	QSAR	QSAR Statistical Methods: Regression analysis, partial least square analysis (PLS) and other multivariate statistical methods. 3D-QSAR approaches like COMFA and COMSIA. Prodrug design: Basic concept, prodrugs to improve patient acceptability, drug solubility, drug absorption and distribution, site specific drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug design.	12	1, 2, 3, 4, 5

Reference Books:

Mouldy Sioud. Target Discovery and Validation Reviews and Protocols: Volume 2 Emerging Molecular Targetsand Treatment Options. 2007 Humana Press Inc.

Darryl León. Scott MarkelIn. Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC. Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London.

Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH.

Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH.

Abby L. Parrill. M. Rami Reddy. Rational Drug Design. Novel Methodology and Practical Applications. ACS Symposium Series; American Chemical Society: Washington, DC, 1999.

J. Rick Turner. New drug development design methodology and analysis. John Wiley & Sons, Inc., New Jersey.

e-Learning Source:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058157/

					-	С	ourse A	Articul	ation 1	Matrix:	(Mappi	ng of CO	s with PO	s and PS	Os)		-	
PO- PS O CO	PO 1	PO 2	PO 3	PO 4	PO 5	PO 6	PO 7	PO 8	PO 9	PO1 0	PO1 1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	3	3	3	1	3	2	2	1	3	3	3	_	3	2	3	_	—	-

CO 2	3	3	3	2	3	2	2	2	3	3	3	—	3	2	3	-	-	—
CO 3	3	3	3	1	3	2	2	1	3	3	3	—	3	2	3	-	—	—
CO 4	3	3	3	2	3	2	2	1	3	3	3	—	3	2	3	-	-	—
CO 5	3	3	3	2	3	2	2	2	3	3	3	-	3	2	3	-	-	-
CO 6	3	3	3	1	3	2	2	1	3	3	3	_	3	2	3	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD	



Effective from Session: 2016-	2017						
Course Code	MPL 204 T	Title of the Course	Clinical Research and Pharmacovigilance	L	Т	Р	С
Year	Ι	Semester	II				4
Pre-Requisite	B Pharm	Co-requisite		4	0	0	4
Course Objectives	2.The importa 3.The concep 4.General me	ance of natural compour	ds and their chemistry and medicinal importance ads as lead molecules for new drug discovery bol for new drug discovery dation of compounds of natural origin ization of simple chemical constituents from natural	sou	irce		

	Course Outcomes
CO1	After studying this subject, students will learn regarding the regulatory requirement of conducting clinical trial.
CO2	After studying this subject, students can demonstrate the types of clinical trial and designs, the responsibility of core team member involved in clinical trial.
CO3	After studying this subject, students will learn Clinical Trial Documentation and ADR assessment and reporting.
CO4	After studying this subject, students can explain the basic aspects, terminologies and establishment of pharmacovigilance.
CO5	After studying this subject, students will know the principles of pharmacovigilance.

U ni t N o.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	Regulatory Perspectives of Clinical Trials:	Origin and Principles of International Conference on Harmonization – Good Clinical Practice (ICH–GCP) guidelines. Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant– Schedule Y, ICMR Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process	12	3
2	Clinical Trials: Types and Design	Experimental Study– RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management	12	3
3	Clinical Trial Documentation-	Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring– Safety Monitoring in CT Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment.Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.	12	3
4	Basic aspects, terminologies and establishment of pharmacovigilance	History and progress of pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing pharmacovigilance centres in Hospitals, Industry and National programmes related to pharmacovigilance. Roles and responsibilities in Pharmacovigilance	12	2
5	Methods, ADR reporting and tools used in Pharmacovigilance	International classification of diseases, International Non– proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data. Pharmacoepidemiology, pharmacoeconomics, safety pharmacology	12	3
	erence Books:			
Dell	ni: Ministry of Health;2001.	Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical P		
Gui	deline. Guideline for Good Clin		Harmonized	1 ripartite
		Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.		
		y David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.		
	Learning Source:	1 ADE/200717/		
<u>htt</u>	ps://www.ncbi.nlm.nih.gov/boc	<u>KS/NBK220717/</u>		

		Course Articulation Matrix: (Mapping of COs with POs and PSOs)																
PO- PS O CO	PO 1	PO 2	PO 3	PO 4	PO 5	PO 6	PO 7	PO 8	PO 9	PO1 0	PO1 1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	2	3	3	3	3	3	3	2	3	3	3	-	3	2	3	-	_	_
CO 2	3	3	3	3	3	2	2	3	2	2	2	-	2	3	2	-	-	-
CO 3	3	2	2	2	2	2	3	1	3	3	3	-	3	3	3	-	-	-
CO 4	3	3	3	3	3	2	2	2	3	2	2	_	3	3	2	_	-	_
CO 5	3	2	3	3	1	1	3	1	2	3	3	_	2	2	3	_	-	_

1-Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator

Sign & Seal of HoD



Effective from Session: 201	6-2017									
Course Code	MPL205P	Title of the Course	Pharmacology Practical- I	L	Т	Р	С			
Year	Ι	Semester	II	0	0	12				
Pre-Requisite	B.Pharm	B.Pharm Co-requisite –								
	1. Discuss th	e pathophysiology phar	macotherapy of certain diseases.							
Course Objectives	Explain th	Explain the mechanism of drug actions at cellular molecular level.								
	3. Understar	d the adverse effects, co	ontraindications and clinical uses of drugs used in treatment	of dise	ease.					

	Course Outcomes
CO1	Able to explain the MOA and the resistance of antimicrobial agents including antivirals and Anti TB in cellular and molecular level
CO2	They can co-relate the pathophysiology behind Gastric ulcer and their therapy with conventional drugs along with new therapeutic approaches.
CO3	Analyze the different types of endocrine hormones and their role, Molecular & Cellular MOA. Further can understand the deficiency and
	excess release related endocrine disorders and their therapy.
CO4	Demonstrate the safe applications of Antiprotozoal & Anticancer drugs in clinical and it also explain about the role
CO5	Correlate about free radical generation with diseased conditions and their therapy with antioxidants, they can also explain about chronotherapy
	and Recent Advances in treatment of neurodegenerative disease, Cancer, Diabetes Mellitus of inflammatory mediators role in Asthma,
	Hypersensitivity reaction.

Exper iment No.	Title of the Experiment	Content of Unit	Contact Hrs.	Mapped CO		
1	Drug response curve	To record the DRC of agonist using suitable isolated tissues preparation.	4	1		
2	Drug effect	To study the effects of antagonist/potentiating agents on DRC of agonist using suitable isolated tissue preparation.	4	1		
3	Matching bioassay	To determine the strength of unknown sample by matching bioassay by using suitable tissue preparation.	4	1		
4	Interpolation bioassay	To determine to the strength of unknown sample by interpolation bioassay by using suitable tissue preparation	4	1		
5	Bracketing bioassay	To determine to the strength of unknown sample by bracketing bioassay by using suitable tissue preparation	4	1		
6	Multiple point bioassay	To determine the strength of unknown sample by multiple point bioassay by using suitable tissue preparation.	4	1		
7	PA2	Estimation of PA ₂ values of various antagonists using suitable isolated tissue preparations.	4	1		
8	Drug effect	4	2			
9	B.P. recording	Recording of rat BP, heart rate and ECG.	4	2		
10	ECG recording	Recording of rat ECG	4	2		
11	Drug absorption	Drug absorption Drug absorption studies by averted rat ileum preparation.				
12	Toxicity studies	ity studies Acute oral toxicity studies as per OECD guidelines.				
13	Toxicity studies	Acute dermal toxicity studies as per OECD guidelines.	4	2		
14	Dose toxicity	Repeated dose toxicity studies- Serum biochemical, haematological, urine analysis, functional observation tests and histological studies.	4	2		
15	Clinical trial	Protocol design for clinical trial.(3 Nos.)	4	3		
16.	ADR design	Design of ADR monitoring protocol.	4	3		
17.	Mutagenicity design	Drug mutagenicity study using mice bone-marrow chromosomal aberration test.	4	3		
18	Docking	In-silico docking studies. (2 Nos.)	4	3		
19.	Pharmacophore screening	In-silico pharmacophore based screening.	4	3		
20.	In silico study	In-silico QSAR	4	3		
21.	ADRreporting	ADR reporting	4	3		
Referen	ce:					
Handboo	ok of Experimental Pha	macology, S.K Kulkarni				
e-Lear	rning Source					
Anima	al simulation Ex- Phar	m				
https	://www.chem.purc	lue.edu/courses/chm224/Lab-Experiments/Exp9_mod.pdf				



	Course Articulation Matrix: (Mapping of COs with POs and PSOs)																	
PO- PSO CO	P O1	PO 2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO1 0	PO1 1	PO1 2	PSO 1	PSO 2	PSO 3	PSO 4	PSO 5	PSO 6
CO1	3	2	2	2	3	3	2	3	3	1	3	-	-	-	-	-	-	-
CO2	3	2	3	3	3	3	2	2	1	1	3	-	-	-	-	-	-	-
CO3	3	3	1	3	1	2	2	1	1	3	3	-	-	-	-	-	-	-
CO4	3	3	3	3	2	2	2	3	2	2	3	-	-	-	-	-	-	-
CO5	3	3	3	3	2	2	1	2	2	1	3	-	-	-	-	-	-	-

Name & Sign of Program Coordinator	Sign & Seal of HoD



Effective from Session: 2017-2018												
Course Code	MRM 301 T	Title of the Course	Research Methodology & Biostatistics	L	Т	Р	С					
Year	Π	Semester	III	4	0		4					
Pre-Requisite		Co-requisite		4	0	0	4					
Course Objectives	2. I 3. H 4. H	Demonstrate the types Explain the CPCSEA Explain the different e	irements for designing the research project. of statistical methods. guidelines for keeping the laboratory animals. ethical principles for conducting the clinical trials. declaration of Helsinki and ICG guidelines									

		Course Outcomes
C	01	After studying this subject, students will learn regarding the strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.
C	02	Students can demonstrate different statistical methods for calculation of data such as t test, ANOVA, wilcoxan rank tests etc.
C	03	Students will learn about history, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality etc.
C	04	After studying this subject, students can explain the CPCSEA guidelines for laboratory animal facility.
C	05	After studying this subject, students will know the Declaration of Helsinki: History, introduction, basic principles for all medical
		research,

Unit No.	Title of the Unit	Content of Unit	Contact Hrs.	Mapped CO
1	General Research Methodology:	Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.	12	3
2	Biostatistics:	Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, type of significance tests, parametric tests(students "t" test, ANOVA, Correlation coefficient, regression), non-parametric tests (wilcoxan rank tests, analysis of variance, correlation, chi square test), null hypothesis, P values, degree of freedom, interpretation of P values.	12	3
3	Medical Research:	History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality.	12	3
4	CPCSEA guidelines for laboratory animal facility:	CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.	12	2

5	Declaration of Helsinki:	History, introduction, basic principles for all medical research, and additional principles for medical research combined with medical care.	12	3								
Referen	Reference Books:											
Del	1.Central Drugs Standard Control Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health;2001.											
	2. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996.											
3.Ethica	al Guidelines for Biomedica	Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.										
4.Textbo	ook of Clinical Trials edited	by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.										
e-Lea	rning Source:											
<u>https:</u>	//drive.google.com/drive/fo	<u> blders/1W4b4NRhqBQWMC14vsBNZcdc2LWFFmcrd?usp=share_link</u>										

						Cou	rse Ar	ticulati	on Ma	trix: (M	apping o	of COs w	ith POs a	nd PSOs)		_	
PO- PS O CO	РО 1	PO 2	PO 3	PO 4	PO 5	PO 6	PO 7	PO 8	PO 9	PO1 0	PO1 1	PO12	PSO1	PSO2	PSO3	PSO4	PSO5	PSO6
CO 1	2	3	3	3	3	3	3	2	3	3	3	-	3	2	3	-	-	
CO 2	3	3	3	3	3	2	2	3	2	2	2	-	2	3	3	-	-	
CO 3	3	2	2	2	2	2	3	1	3	3	3	-	3	3	3	-	-	
CO 4	3	3	3	3	3	2	2	2	3	2	2	-	3	3	3	-	-	
CO 5	3	2	3	3	1	1	3	1	2	3	3	-	2	2	3	-	-	

1-

Low Correlation; 2- Moderate Correlation; 3- Substantial Correlation

Name & Sign of Program Coordinator

Sign & Seal of HoD